Situs Slot Gacor Slot Gacor Gampang Menang Situs Slot Gacor https://gms.dpe.go.th/mobile/public/admin/ckfinder/plugins/fileeditor/situs-judi-slot-terbaik-dan-terpercaya-no-1/ http://portalsewa.mais.gov.my/img/icons/largest/slot-online-gacor-terbaru/ https://new.c.mi.com/th/post/340006/SBOBET__Agen_Judi_Bola_Online_SBOBET88_Resmi_Indon https://new.c.mi.com/th/post/338489/SBOBET__Agen_Bola_Resmi_Layanan_Taruhan_Online_Ter https://new.c.mi.com/th/post/338479/Agen_SBOBET_Indonesia_Terpercaya__Link_Daftar_SBOB https://new.c.mi.com/th/post/338474/Situs_Judi_Bola_Online_Sbobet_dan_Agen_Bola_Terper https://new.c.mi.com/th/post/737547/SBOBET__AGEN_SBOBET_INDONESIA_LOGIN_MOBILE_ONLINE_ https://new.c.mi.com/th/post/735520/SBOBET__Link_Bandar_Sbobet88_Indonesia_Terpercaya_ https://new.c.mi.com/th/post/738763/DAFTAR_SBOBET_88_BOLA_TERMURAH_DAN_TERLENGKAP_BERS https://new.c.mi.com/th/post/735126/SBOBET_MOBILE__Daftar_Judi_Bola_Online__SBOBET88_C https://new.c.mi.com/th/post/737542/SBOBET__Daftar_Judi_Bola_Online__SBOBET88_Casino__ https://new.c.mi.com/th/post/733494/Agen_SBOBET_Indonesia_Terpercaya__Link_Daftar_SBOB
Business

Athira’s alternative Alzheimer’s approach goes into a PhII wall – Endpoints News




PTC Therapeutics’ years-long efforts to push the controversial Duchenne MD drug Translarna into the United States have just encountered its latest setback.

Biotechnology reported a mixed set of data from their confirmatory study of the drug, with a list of key flaws that at least one high-profile analyst believes is unlikely to win over FDA skeptics.

Biotechnology executives were careful to put the spotlight on the positive aspects of the data, which they say paves the way for their next FDA pitch for treating nonsense mutation DMD. And RBC’s Brian Abrahams believes it should keep it in the European market, where it got an early launch on failed sample data. But analysts questioned the poor data the PTC revealed Tuesday morning.

Athira’s alternative Alzheimer’s approach goes into a PhII wall – Endpoints News

Continue reading Endpoints with a free subscription

Unlock this story instantly and join over 1[ads1]44,200 biopharmaceutical professionals who read Endpoints daily – and it’s free.




Source link

Back to top button